Cargando…

213. Prophylactic oral vancomycin for Clostridioides difficile in allogeneic hematopoietic stem cell transplant recipients

BACKGROUND: Allogeneic hematopoietic stem cell transplant (alloHSCT) recipients are at substantial risk for Clostridioides difficile infection (CDI) due to prolonged hospitalization and alteration of the intestinal mucosa and gut microbiota from conditioning regimens, antimicrobials, and immunosuppr...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ogawa, Lauren, Wright, Kaylor, Luk, Alfred
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2022
Materias:	Abstracts
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9752381/ http://dx.doi.org/10.1093/ofid/ofac492.290

Ejemplares similares

696. Effectiveness of Oral Vancomycin as Prophylaxis against Clostridioides difficile Infection in Hematopoietic Stem Cell Transplant Patients
por: Reitmeyer, Kelly M, et al.
Publicado: (2023)

Incidence Rates and Risk Factors of Clostridioides difficile Infection in Solid Organ and Hematopoietic Stem Cell Transplant Recipients
por: Ilett, Emma E, et al.
Publicado: (2019)

Prophylactic Trimethoprim-Sulfamethoxazole for Allogeneic Hematopoietic Stem Cell Transplant Recipients During the Pre-engraftment Period
por: Gaffney, Kelly J., et al.
Publicado: (2023)

Randomized Controlled Trial of Oral Vancomycin Treatment in Clostridioides difficile-Colonized Patients
por: Fishbein, Skye R. S., et al.
Publicado: (2021)

722. Effectiveness of Fidaxomicin versus Oral Vancomycin in the Treatment of Recurrent Clostridioides difficile
por: Rinaldi, Alyssa, et al.
Publicado: (2020)

Comparison of fidaxomicin to oral vancomycin for the treatment of Clostridioides difficile infection in hospitalized patients
por: Rao, A. Krishna, et al.
Publicado: (2022)

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients
por: Johnson, Tanner M, et al.
Publicado: (2021)

Incidence and Outcomes Associated With Clostridioides difficile Infection in Solid Organ Transplant Recipients
por: Hosseini-Moghaddam, Seyed M., et al.
Publicado: (2021)

Assessment of oral health condition in recipients of allogeneic hematopoietic cell transplantation
por: Reis, Thiago de Carvalho, et al.
Publicado: (2022)

Early Clostridium difficile Infection during Allogeneic Hematopoietic Stem Cell Transplantation
por: Kinnebrew, Melissa A., et al.
Publicado: (2014)

1376. Oral Vancomycin as Secondary Prophylaxis Against Clostridioides difficile Infection in Pediatric Patients
por: Bao, Hongkai, et al.
Publicado: (2020)

728. Prophylactic Vancomycin Therapy in Long Term Care Patients Colonized with Clostridioides difficile to Reduce Hospital-Acquired C. diff Infection
por: Muneer, Sumayya, et al.
Publicado: (2020)

Impact of Clostridioides difficile Therapy on Nosocomial Acquisition of Vancomycin-Resistant Enterococci
por: Correa-Martínez, Carlos L., et al.
Publicado: (2021)

Genetic Mechanisms of Vancomycin Resistance in Clostridioides difficile: A Systematic Review
por: Eubank, Taryn A., et al.
Publicado: (2022)

Utilizing vancomycin as secondary prophylaxis for the prevention of recurrent Clostridioides difficile infection
por: Kristen, Zeitler, et al.
Publicado: (2023)

800. Oral Vancomycin Prophylaxis Against Clostridioides difficile in Patients Admitted to a Tertiary Academic Medical Center
por: Kopelman, David B, et al.
Publicado: (2020)

Human Cytomegalovirus Latency and Reactivation in Allogeneic Hematopoietic Stem Cell Transplant Recipients
por: Stern, Lauren, et al.
Publicado: (2019)

Donor–Recipient Story in Allogeneic Hematopoietic Stem Cell Transplantation
por: Kum, Elena, et al.
Publicado: (2021)

Cutaneous Legionella infections in allogeneic hematopoietic cell transplantation recipients
por: Vaidya, Toral, et al.
Publicado: (2020)

2670. Clostridioides difficile Infection (CDI) in Solid-Organ (SOT) and Hematopoietic Stem Cell Transplant (HCT) Recipients: A Prospective Multinational Study
por: Blumberg, Emily, et al.
Publicado: (2019)

2411. One Dose Vancomycin Prophylaxis for In-Hospital Clostridioides difficile - Associated Disease
por: Papic, Neven, et al.
Publicado: (2019)

Clostridioides difficile and Vancomycin-Resistant Enterococci in COVID-19 Patients with Severe Pneumonia
por: Bogdanová, Kateřina, et al.
Publicado: (2021)

380. A molecular epidemiological exploration of reduced vancomycin susceptibility in Clostridioides difficile
por: Eubank, Taryn A, et al.
Publicado: (2022)

679. Retrospective Analysis of Vancomycin and Fidaxomicin for the Treatment of Recurrent Clostridioides difficile Infection
por: Fabian, Amy, et al.
Publicado: (2023)

WU and KI Polyomaviruses in Respiratory Samples from Allogeneic Hematopoietic Cell Transplant Recipients
por: Kuypers, Jane, et al.
Publicado: (2012)

Toxoplasma Encephalitis in an Allogeneic Hematopoietic Stem Cell Transplant Recipient in Korea
por: Park, Soo-Kyung, et al.
Publicado: (2012)

2433. Oral Vancomycin Plus Intravenous Metronidazole for Severe Clostridioides difficile Infection in Critically Ill Patients
por: Vega, Ana D, et al.
Publicado: (2019)

Efficacy of oral vancomycin prophylaxis for prevention of Clostridioides difficile infection: a systematic review and meta-analysis
por: Tariq, Raseen, et al.
Publicado: (2021)

657. Impact of Oral Vancomycin Duration on Clostridioides difficile Recurrence in Patients Requiring Concurrent Systemic Antibiotics
por: Marsh, Kassandra, et al.
Publicado: (2023)

Cadazolid vs Vancomycin for the Treatment of Clostridioides difficile Infection: Systematic Review with Meta-analysis
por: Muhammad, Aziz, et al.
Publicado: (2020)

Which is the Preferred Regimen for Non-Severe Clostridioides difficile Infection in Korea, Vancomycin or Metronidazole?
por: Kim, Jieun, et al.
Publicado: (2022)

2164. Resistome patterns associated with vancomycin non-susceptibility in clinical Clostridioides difficile isolates
por: Eubank, Taryn A, et al.
Publicado: (2023)

Intestinal Dysbiosis and Risk of Posttransplant Clostridioides difficile Infection in a Longitudinal Cohort of Liver Transplant Recipients
por: Gomez-Simmonds, Angela, et al.
Publicado: (2022)

Diagnosis and treatment of viral diseases in recipients of allogeneic hematopoietic stem cell transplantation
por: Lin, Ren, et al.
Publicado: (2013)

Acinetobacter baumannii Septicemia in a Recipient of an Allogeneic Hematopoietic Stem Cell Transplantation
por: Al-Anazi, Khalid Ahmed, et al.
Publicado: (2012)

Quantitative characterization of T-cell repertoire in allogeneic hematopoietic stem cell transplant recipients
por: Yew, P Y, et al.
Publicado: (2015)

Elevated Galectin-3 Plasma Concentrations in Recipients of Allogeneic Hematopoietic Cell Transplantation
por: DeFilipp, Zachariah, et al.
Publicado: (2019)

Clinically relevant germline variants in allogeneic hematopoietic stem cell transplant recipients
por: Lahtinen, Atte K., et al.
Publicado: (2022)

Nutritional modulation of the gut microbiome in allogeneic hematopoietic stem cell transplantation recipients
por: Muratore, Edoardo, et al.
Publicado: (2022)

2414. Effectiveness of Oral Vancomycin for Prevention of Healthcare Facility-Onset Clostridioides difficile Infection in High-Risk Patients
por: Johnson, Steven W, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_buho2ckelo4lraktd9vbeciom3